CBL-514 selectively induces apoptosis of fat cells

Details of a new injection that targets fat cells will be released at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2). Studies show that the new drug, CBL-514, reduces levels of subcutaneous and visceral fat. The data also suggest that it helps limit weight regain after people stop taking GLP-1 receptor agonist drugs (GLP1-RAs), says Dr. W. Timothy Garvey of the University of Alabama at Birmingham.

CBL-514 selectively induces apoptosis (self-destruction) of adipocytes, or fat cells, while leaving other cells untouched.

In phase 2 clinical trials, the drug reduced the volume of subcutaneous adipose tissue—the layer of fat that lies just beneath the skin and can be “pinched”—with 69.6% of treated participants achieving a reduction of at least 150 mL at the eight-week follow-up, compared with 0% of those receiving a placebo.

In preclinical studies (animal models), it reduced weight and levels of subcutaneous and visceral adipose tissue (VAT). Visceral fat is hidden deep within the abdomen, wrapped around the internal organs. It is very metabolically active and a key driver of insulin resistance, type 2 diabetes and cardiometabolic conditions such as heart attacks and strokes.

More weight was lost when the drug was given along with the GLP1-RA tirzepatide. In addition, rats given CBL-514 and tirzepatide regained less weight when tirzepatide was stopped than rats given tirzepatide alone.

The hypothesis is that the reduction in fat cells limits the amount of fat that can be reaccumulated, slowing weight regain.

While GLP1-RAs are highly effective for weight loss, many people regain weight after stopping treatment. The hope is that CBL-514 will help people keep weight off—allowing them to sustain the health benefits of weight loss, such as improvements in blood pressure, blood sugar and cholesterol, says Garvey. However, research is needed to prove this.

For the latest analysis, Garvey and Yu-Fang Ling of the drug’s developer, Caliway Biopharmaceuticals, in New Taipei City, Taiwan, used data on a subgroup of participants from the phase 2 trials (CBL-0204 and CBL-0205) to assess CBL-514’s effect on visceral fat in human subjects. They focused on trial participants for whom MRI data were available.

The participants (BMI 22–30 kg/m²) (age range 36.4 years to 42.4 years) received injections of up to 600 mg of CBL-514 (n=23) or placebo (n=17) into the lower abdomen every three weeks for up to 12 weeks. The exact number of injections depended on the thickness of their abdominal fat.

The number of injections was reduced as the participant’s fat thickness decreased, and injections were stopped when the thickness reached a low enough level. MRI scans were used to measure visceral adipose tissue at baseline, four weeks after the last treatment and eight to 12 weeks after the last treatment.

VAT volume was similar in the two groups at baseline: 563.85 ml in the CBL-514 group and 659.81 ml in the placebo group. It then decreased in those receiving the drug and increased in those given the placebo.

Four weeks after the last treatment, average VAT volume had decreased by 12.01% from baseline in the CBL-514 group, while it had increased by 5.68% in the placebo group, representing a between-group difference of 17.69 percentage points.

At the later follow-up—eight weeks after the last treatment in CBL-0205 and 12 weeks after the last treatment in CBL-0204—average VAT volume was 10.45% lower than at baseline in the CBL-514 group, while it had increased by 11.76% in the placebo group, representing a between-group difference of 22.21 percentage points.

Other than mostly mild to moderate and transient injection-site reactions, such as pain, swelling and redness, CBL-514 was generally well tolerated, with no serious adverse events reported.

The researchers conclude that CBL-514 significantly reduced abdominal VAT volume compared with placebo—and that the research as a whole shows that the drug can reduce both visceral and subcutaneous fat.

Garvey says, “We expect that patients will be pleased by the cosmetic effects, such as the flatter stomach that can come with subcutaneous fat loss. But it is the reduction in body weight, loss of visceral fat and the improvements in blood pressure, cholesterol and the like that should be associated with this that will be important for health.”

He adds that liposuction and abdominoplasty only address subcutaneous fat and are more invasive.

“This is a highly innovative approach to obesity pharmacotherapy that has produced some remarkable results in early human trials,” says Garvey.

Recruitment for the first of two phase 3 trials is underway. These randomized placebo-controlled studies will evaluate the safety and efficacy of CBL-514 for nonsurgical abdominal fat reduction, with the first results expected at the end of next year.

Provided by
European Association for the Study of Diabetes

Who’s behind this story?

Swati Mestri

Swati Mestri holds a bachelor’s degree in Electronics Engineering and has worked as a content editor since 2019. She has experience editing research documents across technology, health care, and materials science, and has a particular interest in technology and space.

Full profile →

Robert Egan

Bachelor’s in mathematical biology, Master’s in creative writing. Well-traveled with unique perspectives on science and language.

Full profile →